ArriVent BioPharma (NASDAQ:AVBP) Stock Gets Price Target Trim from HC Wainwright

ArriVent BioPharma (NASDAQ:AVBP) had its target price lowered by HC Wainwright from $47.00 to $27.00 in a research report released on Thursday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

AVBP has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ArriVent BioPharma in a report on Tuesday, September 22nd. Jefferies Financial Group set a $18.00 price target on shares of ArriVent BioPharma in a report on Tuesday. BTIG Research dropped their price target on shares of ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday. Truist Financial cut their price objective on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Finally, JonesTrading decreased their price objective on shares of ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ArriVent BioPharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.44.

ArriVent BioPharma Price Performance

Shares of ArriVent BioPharma stock opened at $16.73 on Thursday. The stock has a market cap of $824.96 million, a PE ratio of -4.62 and a beta of 1.34. The firm has a fifty day moving average price of $28.76 and a 200 day moving average price of $29.26. ArriVent BioPharma has a 1 year low of $11.36 and a 1 year high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, equities analysts expect that ArriVent BioPharma will post -4.05 EPS for the current year.

Institutional Trading of ArriVent BioPharma

Several institutional investors have recently made changes to their positions in AVBP. Quantbot Technologies LP purchased a new stake in shares of ArriVent BioPharma in the 2nd quarter valued at approximately $59,000. Jupiter Topco LLC acquired a new position in shares of ArriVent BioPharma in the second quarter worth $226,000. Arizona State Retirement System acquired a new position in shares of ArriVent BioPharma in the second quarter worth $233,000. Glenmede Trust Co. NA purchased a new stake in shares of ArriVent BioPharma during the first quarter worth $209,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of ArriVent BioPharma during the first quarter worth $209,000. Hedge funds and other institutional investors own 9.48% of the company’s stock.

Key Headlines Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for ArriVent’s third quarter and full-year 2026, as well as the first, second and third quarters of 2027. The firm also increased its FY2027 forecast to a loss of $3.97 per share from a projected loss of $4.24, indicating expectations for narrower losses over time.
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $27 price target. That target implies meaningful upside from the stock’s recent trading level and may help support investor sentiment.
• Neutral Sentiment: The estimate revisions were not uniformly positive: HC Wainwright lowered its Q4 2027 EPS forecast to a loss of $1.02 from $0.93. The company remains unprofitable, with consensus estimates calling for a $4.11-per-share loss for the current year.
• Negative Sentiment: Separate reports said HC Wainwright cut its price target for ArriVent, while Wall Street Zen lowered its stock rating. These actions could weigh on the shares despite HC Wainwright’s continued Buy recommendation. ArriVent BioPharma Stock Price Target Cut by HC Wainwright ArriVent BioPharma Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Citigroup and JonesTrading were also reported to issue pessimistic forecasts for AVBP, adding to the cautious analyst backdrop. Citigroup Issues Pessimistic Forecast for ArriVent BioPharma JonesTrading Issues Pessimistic Forecast for ArriVent BioPharma

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.